These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19229297)

  • 1. Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R.
    Sheng Z; Wang SZ; Green MR
    EMBO J; 2009 Apr; 28(7):866-76. PubMed ID: 19229297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake.
    Devireddy LR; Gazin C; Zhu X; Green MR
    Cell; 2005 Dec; 123(7):1293-305. PubMed ID: 16377569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
    Lin H; Monaco G; Sun T; Ling X; Stephens C; Xie S; Belmont J; Arlinghaus R
    Oncogene; 2005 May; 24(20):3246-56. PubMed ID: 15735695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism.
    Fernández de Mattos S; Essafi A; Soeiro I; Pietersen AM; Birkenkamp KU; Edwards CS; Martino A; Nelson BH; Francis JM; Jones MC; Brosens JJ; Coffer PJ; Lam EW
    Mol Cell Biol; 2004 Nov; 24(22):10058-71. PubMed ID: 15509806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells.
    Essafi A; Fernández de Mattos S; Hassen YA; Soeiro I; Mufti GJ; Thomas NS; Medema RH; Lam EW
    Oncogene; 2005 Mar; 24(14):2317-29. PubMed ID: 15688014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of β-catenin and STAT1 in chronic myeloid leukemia cells.
    Yang KT; Wang MC; Chen JY; Hsu MC; Hung WC
    J Cell Physiol; 2011 Nov; 226(11):2849-56. PubMed ID: 21935931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.
    Nishihara T; Miura Y; Tohyama Y; Mizutani C; Hishita T; Ichiyama S; Uchiyama T; Tohyama K
    Int J Hematol; 2003 Oct; 78(3):233-40. PubMed ID: 14604282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of CCL9/MIP-1gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells.
    Iotti G; Ferrari-Amorotti G; Rosafio C; Corradini F; Lidonnici MR; Ronchetti M; Bardini M; Zhang Y; Martinez R; Blasi F; Calabretta B
    Oncogene; 2007 May; 26(24):3482-91. PubMed ID: 17160016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
    J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
    Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
    Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway.
    Gesbert F; Sellers WR; Signoretti S; Loda M; Griffin JD
    J Biol Chem; 2000 Dec; 275(50):39223-30. PubMed ID: 11010972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
    Dai Y; Rahmani M; Pei XY; Dent P; Grant S
    Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
    Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway.
    Kurosu T; Wu N; Oshikawa G; Kagechika H; Miura O
    Apoptosis; 2010 May; 15(5):608-20. PubMed ID: 20094798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
    Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
    Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
    Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.